. Regulation of eosinophil function by phosphatidylinositol-specific PLC and cytosolic PLA 2. Am J Physiol Lung Cell Mol Physiol 281: L844-L851, 2001.-We examined the regulatory role of cytosolic phospholipase A 2 (cPLA2) and phosphatidylinositol (PI)-specific phospholipase C (PLC) in the degranulation of human eosinophils and leukotriene (LT) C 4 synthesis. Activation with formyl-Met-Leu-Phe ϩ cytochalasin B (fMLP/B) caused a time-dependent release of eosinophil peroxidase (EPO) and LTC 4, which was inhibited by pertussis toxin. By immunoblotting, eosinophil PLC-␤2 and -␥2 isoforms were identified, and PLC activation was measured as a function of inositol 1,4,5-trisphosphate concentration. Stimulated release of EPO and intracellular Ca 2ϩ concentration was inhibited by ET-18-OCH 3, a PI-PLC inhibitor, whereas trifluoromethylketone (TFMK), a cPLA2 blocker, had no inhibitory effect. Both TFMK and ET-18-OCH 3 attenuated stimulated arachidonate release and LTC4 secretion, suggesting that activation of both PLC and cPLA 2 is essential for LTC4 synthesis caused by fMLP/B. The structurally unrelated protein kinase C inhibitors bisindolylmaleimide, Ro-31-8220, and Go-6976 all blocked fMLP/B-induced EPO release but not LTC4 secretion. 1,2-bis(2-Aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid acetoxymethyl ester, an intracellular Ca 2ϩ chelator, suppressed both EPO release and LTC4 secretion. We found that fMLP/B-induced LTC 4 secretion from human eosinophils is regulated by PI-PLC through calcium-mediated activation of cPLA 2. However, cPLA2 does not regulate eosinophil degranulation.
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arachidonate; protein kinase C; calcium concentration; phospholipase C isoforms EOSINOPHIL ACTIVATION AND SECRETION of lipid mediators such as platelet-activating factor (PAF), leukotriene (LT) C 4 , and granular proteins are thought to have a major role in the pathophysiology of eosinophil-associated disease including human asthma (2, 8, 17, 23) . However, the signaling pathways that regulate eosinophil secretion of preformed granular proteins and the synthesis and release of lipid mediators are incompletely characterized.
Recent evidence suggests that G protein or protein tyrosine kinase couples cell surface receptors to phospholipase C (PLC) (11) . G protein-dependent PLC activation appears to involve the PLC-␤2 isoform, which is known to be activated by N-formyl-Met-Leu-Phe (fMLP) in neutrophils (6, 7) . In certain cases, receptor-mediated activation of PLC is sensitive to pertussis toxin (PTX), which catalyzes ADP-ribosylation of certain G protein ␣-units in intact cells, resulting in the uncoupling of these G proteins from cell surface receptors (22) . By contrast, receptor-activated protein tyrosine kinases induce phosphoinositide hydrolysis by phosphorylating either PLC-␥1 or PLC-␥2. The activated PLC catalyzes the hydrolysis of phosphotidylinositol (8, 11) biphosphate into two intracellular second messengers, inositol 1,4,5-trisphosphate [Ins(1,4,5)P 3 ] and 1,2-diacylglycerol (DAG), which, in turn, increase intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) and activate protein kinase C (PKC), respectively (1) . Although the specific transmembrane signaling events for triggering eosinophil degranulation have not been elucidated, it has been suggested that PLC is involved in eosinophil degranulation induced by PAF (15) or immobilized immunoglobulin (13) .
The intracellular 85-kDa cytosolic PLA 2 (cPLA 2 ) is an important enzyme in mediating agonist-induced arachidonic acid (AA) release and eicosanoid production (5, 18, 26) . cPLA 2 is posttranslationally regulated by both phosphorylation (14, 18, 19, 27) and an increase in intracellular calcium (3, 4, 25) . The role of PLA 2 in regulating eicosanoid syntheses in eosinophils is widely recognized; however, the role of phospholipases in regulating eosinophil degranulation remains to be defined. We have reported previously that PLA 2 regulates both degranulation and LTC 4 synthesis by use of two broad PLA 2 inhibitors, mepacrine and 4-bromophenyl bromide (BPB) (28) .
The objective of this study was to examine the mechanisms of eosinophil degranulation and LTC 4 secretion after G protein-coupled receptor activation by fMLP ϩ cytochalasin B (fMLP/B). Our data suggest that phosphatidylinositol (PI)-specific PLC is the critical enzyme for both eosinophil degranulation and synthesis of the cysteinyl LTC 4 . Inhibition of PI-PLC blocks fMLP/Binduced degranulation, whereas inhibition of cPLA 2 selectively inhibits LTC 4 secretion caused by fMLP/B. Our data demonstrate that PI-PLC-mediated calcium influx and PKC activation, but not cPLA 2 -activation, are essential for eosinophil degranulation, whereas PI-PLC-mediated calcium influx and cPLA 2 activation are involved in LTC 4 synthesis and secretion from human eosinophils.
MATERIALS AND METHODS
Reagents. fMLP, cytochalasin B (B), and rabbit IgG were purchased from Sigma Chemical (St. Louis, MO). Anti-PLC-␤1 and -␤2 rabbit polyclonal antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). ET-18-OCH 3, PTX, bisindolylmaleimide, Ro-31-8220, Go-6976, 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid acetoxymethyl ester (BAPTA-AM), and fura 2-AM were purchased from Calbiochem (San Diego, CA). LTC4 enzyme immunoassay kits and arachidonyl trifluoromethylketone (TFMK) were purchased from Cayman Chemical (Ann Arbor, MI). Anti-rabbit IgG (horseradish peroxidase-linked whole antibody from donkey) and [5,6,8,9,11,12,14,15- 3 H]arachidonic acid and D-myo-Ins(1,4,5)P3 radioimmunoassay kits were purchased from Amersham Life Science (Arlington Heights, IL). All supplies for eosinophil isolation were obtained from Miltenyi Biotech (Sunnyvale, CA). 1-Palmitoyl-2-[ 14 C]arachidonylphosphatidylcholine was purchased from NEN Life Science Products (Boston, MA).
Isolation of human peripheral blood eosinophils. Eosinophils were isolated from mildly atopic human volunteers by a modification of the negative selection immunomagnetic separation technique (10) . The treated granulocyte cell suspension was passed through a 1 ϫ 10-cm steel wool column within a 0.6-T MACS magnet (Becton Dickinson, Mountain View, CA). Total cell counts were made in a hemocytometer, and the purity of the cells was assessed by differential counts from Wright-Giemsa-stained cytocentrifuge preparations. The viability of isolated eosinophils was confirmed by trypan blue exclusion. Cell preparations contained Ͼ99% eosinophils and were kept on ice until used.
Measurement of eosinophil peroxidase release and LTC 4 secretion. The release of both eosinophil peroxidase (EPO) and LTC 4 was determined in experimental cells from the same experiments. Eosinophils (2.5 ϫ 10 5 /250 l) were first treated with either buffer, ET-18-OCH3 (0.1-10 M), TFMK (1-30 M), PTX (1-300 ng/ml), bisindolylmaleimide (0.1-10 M), Ro-31-8220 (0.1-10 M), Go-6976 (0.01-1 M), or BAPTA-AM (0.1-10 M) before activation with 1 M fMLP ϩ 5 g/ml cytochalasin B (fMLP/B). Thirty minutes later, the reaction was terminated by centrifugation, and the supernatant was collected and stored at Ϫ80°C until analyzed. Briefly, 50 l of sample or EPO standard were mixed with 100 l of substrate (final concentrations 0.01% hydrogen peroxide, 6 mM o-phenylenediamine, and 0.06% Triton X-100 dissolved in 60 mM Tris, pH 8.0) in a polystyrene 96-well microplate and incubated for 30 min at room temperature. Reactions then were stopped by adding 50 l of 4 M H 2SO4, and absorbance was measured at 490 nm in a thermoregulating microplate absorbance spectrophotometer (Thermomax; Molecular Devices, Menlo Park, CA). Final EPO concentrations then were calculated from standard curves fitted by four-parameter analysis.
A separate aliquot of these same cells was used to measure the stimulated secretion of LTC 4 by use of an EIA kit (Cayman Chemical, Ann Arbor, MI).
Measurement of eosinophil Ins (1, 4, 5 )P 3 concentration. Eosinophils (5 ϫ 10 6 cells/intervention) in Hanks' balanced salt solution (HBSS) buffer were incubated for 20 min with ET-18-OCH 3 or TFMK before fMLP/B stimulation. The reaction was stopped at the indicated time for kinetic study or at 10 s for the other experiments by the addition of an equal volume of ice-cold 15% trichloroacetic acid and incubated for 20 min on ice. After centrifugation, the supernatant was removed and washed three times with 10 volumes of water-saturated diethyl ether. An aliquot of each neutralized supernatant (100 l) was then used to determine the Ins(1,4,5)P 3 concentration. Ins(1,4,5)P 3 was measured by competitive radiobinding assay following manufacturer's instructions (Amersham Life Science).
Measurement of eosinophil arachidonate release. Eosinophils (10 7 cells/ml) were incubated with 0.5 Ci/ml [ 3 H]arachidonate (AA) overnight and washed three times with HBSS containing 0.2% bovine serum albumin. The cells were divided into aliquots (10 6 cells/100 l final volume) and were treated with inhibitors at 37°C for 20 min before activation with fMLP/B activation. After centrifugation, a 90-l aliquot of the supernatant was counted in 2 ml of scintillation solvent with the Beckman scintillation counter.
Measurement of eosinophil cPLA2 activity. cPLA2 activity was measured as described by Kim et al. (12) . A total of 2 ϫ 10 6 eosinophils was preincubated with or without ET-18-OCH3 or TFMK for 20 min before activation with either buffer alone or fMLP/B for 5 min. The pellet was resuspended in 70 l of disruption buffer [20 mM Tris, pH 8.0, 2.5 mM EDTA, 10 g/ml leupeptin, 5 g/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM Na3VO4, 50 mM NaF, and 5 g/ml pepstatin] and treated with 5 mM dithiothreitol on ice for 5 min to inactivate soluble PLA2. The reaction was initiated by adding 10 l of substrate ([ 14 C]PAPC; final concentration 9 M) to cell lysate for 30 min at 37°C. Extraction was performed by adding 560 l of Dole's reagent (heptane-isopropyl alcohol-1 N H2SO4; 400:390:10 vol/vol) to sample tube, followed by 110 l of H2O. The upper layer was transferred to 800 l of hexane containing 25 mg of silica gel, and an aliquot (upper layer) was used to count the radioactivity with a liquid scintillation counter.
Immunoblotting analysis. An aliquot of treated eosinophils (2 ϫ 10 6 cells/intervention) was incubated for 20 min on ice with ice-cold lysis buffer (in mM: 20 Tris ⅐ HCl, 30 Na4P2O7, 50 NaF, 40 NaCl, and 5 EDTA, pH 7.4) containing 1% Nonidet P-40, 10 g/ml leupeptin, 5 g/ml aprotinin, 5 g/ml pepstatin, 5 g/ml chymostatin, 1 mM PMSF, 2 mM Na3VO4, and 0.5% deoxycholic acid. By centrifugation, nuclear and cellular debris were discarded, and the treated supernatant was boiled for 5 min. Proteins were subjected to 7% SDS-PAGE for detection of PLC isoforms. Membrane containing resolved proteins was exposed to 3% BSA in 20 mM Tris, 500 mM NaCl, and 0.05% Tween 20, pH 7.5 (TBS-T) before addition of primary antibodies (anti-rabbit IgG, anti-PLC-␤2, and 1 g/ml blocking peptide). Membranes were washed three times with TBS-T, and bound antibody was detected with horseradish peroxidase-conjugated donkey anti-rabbit IgG as secondary antibody and developed using ECL Hyperfilm.
Measurement of eosinophil [Ca 2ϩ ]i. Eosinophils (10 7 cells/ ml) were incubated in calcium-free HBSS buffer with 2.5 M fura 2-AM for 120 min at 37°C. Fura-loaded cells (2 ϫ 10 cells/sample) were dispensed in the cuvettes and allowed to equilibrate at 37°C for 2 min before preincubation with inhibitors. Twenty minutes later, fMLP/B was added, and fluorescence emission was continuously monitored for 5 min to determine the relative alternation in intensity. The concentration of free Ca 2ϩ was maintained at 120 Ϯ 20 M by using 2 mM EGTA and 1.25 mM CaCl2 in experimental buffer with eosinophils. The fluorescence intensity was monitored using excitation and emission wavelengths of 340 and 500 nm.
Assessment of eosinophil viability. In all experimental studies, trypan blue exclusion analysis was performed to assess whether PTX, ET-18-OCH 3, TFMK, bisindolylmaleimide, or Ro-31-8220 affected eosinophil viability. Aliquots of 10 4 eosinophils were incubated with various concentrations of these inhibitors at 37°C for 120 min (PTX) or for 20 min (ET-18-OCH3, TFMK, bisindolylmaleimide, or Ro-31-8220). Cells remained Ͼ98% viable as determined with a hemocytometer.
Statistical analysis. Data are expressed as means Ϯ SE. The difference between various treatment groups was assessed by ANOVA, and where differences were found between groups, statistical significance was determined using a Mann-Whitney unpaired t-test. Statistical significance was claimed when P Ͻ 0.05. 4 secretion: markers of eosinophil activation. fMLP/B induced secretion of EPO and LTC 4 in concentration-dependent manner (Fig. 1) . At 1 M fMLP ϩ 5 g/ml cytochalasin B (fMLP/B), EPO release was 2,561 Ϯ 979 vs. 121 Ϯ 14 ng/ml for unstimulated cells (Fig. 1A , P Ͻ 0.05); LTC 4 secretion increased from 41 Ϯ 33 pg/ml (buffer stimulated) to 1,368 Ϯ 575 pg/ml (P Ͻ 0.05) (Fig. 1C) . This concentration (1 M) of fMLP, which caused substantial, but submaximal, release of both EPO and LTC 4 , was used for all subsequent experiments.
RESULTS

EPO release and LTC
A time-related increase in EPO release and LTC 4 secretion also was demonstrated after fMLP/B activation (Fig. 1, B and D) . At 1 min, EPO release was maximal (3,043 Ϯ 865 vs. 72 Ϯ 16 ng/ml for unstimulated controls; P Ͻ 0.01) and was sustained thereafter. In contrast to the rapid release of preformed eosinophil granular protein, LTC 4 secretion was greatest at 10 min (1,476 Ϯ 500 vs. 89 Ϯ 82 pg/ml for unstimulated controls; P Ͻ 0.01). Neither buffer alone nor cytochalasin B (no fMLP) caused secretion of EPO or LTC 4 .
Inhibition of stimulated Ins (1, 4, 5 )P 3 concentration, EPO release, and LTC 4 secretion by PTX. PTX (1-100 ng/ml) caused concentration-dependent inhibition of Ins(1,4,5)P 3 production in eosinophils ( Fig. 2A) , EPO release (Fig. 2B) , and LTC 4 secretion (Fig. 2C) . Ins(1,4,5)P 3 concentration decreased from 0.84 Ϯ 0.14 to 0.39 Ϯ 0.10 pmol/10 6 cells (P Ͻ 0.05), and EPO release of 1,782 Ϯ 410 ng/ml was blocked completely to baseline (178 Ϯ 114 ng/ml) after PTX (P Ͻ 0.05). Similarly, stimulated LTC 4 secretion of 1,223 Ϯ 117 pg/ml also was blocked completely with 300 ng/ml PTX (P Ͻ 0.001 vs. stimulated cells, no PTX).
PI-PLC isoforms in human eosinophils. Bands of 120 and 140 kDa were detected on immunoblots after PLC-␤2 antibody and -␥2 antibody staining; neither PLC-␤1 (a weak band shown in lane 2 of Fig. 3A was nonspecific because blocking peptide never reduced this weak band) nor PLC-␥1 bands were identified (Fig.  3, A and B) . To confirm that each antibody was reacting with its intended target protein, PLC antibodies were preincubated with specific blocking peptide before immunoblotting. The 120-and 140-kDa bands were substantially reduced [ Fig. 3, A (lane 4) and B (lane 4)] . 3 and TFMK. PLC activation was measured as a function of Ins(1,4,5)P 3 production (Fig. 4A ). In the unstimulated state, Ins(1,4,5)P 3 was 0.27 Ϯ 0.08 pmol/ concentration decreased to baseline level within 2 min (0.32 Ϯ 0.07 pmol/10 6 cells; P Ͻ 0.05). For eosinophils pretreated with selective PI-PLC inhibitor ET-18-OCH 3, Ins(1,4,5)P 3 concentration decreased from 0.84 Ϯ 0.08 to 0.43 Ϯ 0.11 pmol/10 6 cells at 10 s (P Ͻ 0.01). In contrast, TFMK, a cPLA 2 inhibitor, had no inhibitory effect on Ins(1,4,5)P 3 production after stimulation with fMLP/B. 3 attenuated the stimulated release of EPO from 1,926 Ϯ 196 to 493 Ϯ 151 ng/ml (P Ͻ 0.05) (Fig. 5) . In contrast, EPO release caused by fMLP/B activation was unchanged even after treatment with the greatest concentration of TFMK. Cells remained viable throughout the experimental intervention (data not shown). 3 and TFMK. Concentration-dependent inhibition of fMLP/B-induced AA release and LTC 4 secretion was demonstrated for eosinophils treated with ET-18-OCH 3 or TFMK (Fig. 6, A and B) .
Ins(1,4,5)P 3 concentration and inhibition by ET-18-OCH
EPO release and inhibition by ET-18-OCH 3 and TFMK. Pretreatment of cells with ET-18-OCH
Inhibition of stimulated AA release and LTC 4 secretion by ET-18-OCH
ET-18-OCH 3 blocked the stimulated AA release from 379 Ϯ 52 to 178 Ϯ 80 cpm (P Ͻ 0.05); TFMK caused a decrease to 153 Ϯ 34 cpm (P Ͻ 0.01 vs. fMLP/B activated, no TFMK). Stimulated LTC 4 secretion (no ET-18-OCH 3 ) was 2,450 Ϯ 667 vs. 610 Ϯ 398 pg/ml after 10 M ET-18-OCH 3 (P Ͻ 0.05). Similarly, substantial inhibition of LTC 4 secretion was obtained for cells treated with TFMK (P Ͻ 0.01 vs. fMLP/B activated, no TFMK). The concentrations of ET-18-OCH 3 and TFMK used in these experiments had no effect on cell viability (data not shown).
Inhibition of stimulated cPLA 2 activity by TFMK and ET-18-OCH 3 . To assess the effect of TFMK or ET-18-OCH 3 on fMLP/B-stimulated cPLA 2 activation, cPLA 2 activity was assessed in cells pretreated with various concentrations of TFMK and ET-18-OCH 3 . TFMK inhibited fMLP-stimulated cPLA 2 activity in a concentration-dependent manner, with maximum inhibition of 73% of stimulated control at 30 M. At the concentrations that blocked both fMLP/B-induced LTC 4 secretion and AA release, ET-18-OCH 3 had no significant inhibitory effect on stimulated cPLA 2 activity (Fig. 7) , indicating that inhibition of LTC 4 secretion and [ 3 H]AA release was not caused by inhibition of cPLA 2 .
Inhibition of stimulated EPO release and LTC 4 secretion by PKC inhibitors and intracellular Ca
2ϩ chelator. The regulatory role of PKC in stimulated EPO release and LTC 4 secretion was assessed using bisindolylmaleimide and Ro-31-8220, two structurally dif- ferent broad spectrum of PKC inhibitors. Bisindolylmaleimide or Ro-31-8220 attenuated the stimulated EPO release (Fig. 8A) but not LTC 4 secretion (Fig. 8B) . Go-6976, a Ca 2ϩ -dependent PKC-␣ and -␤1 isozyme inhibitor, also attenuated the stimulated EPO release but not LTC 4 secretion (Fig. 8) . These data suggest that PKCs, possibly the classical Ca 2ϩ -dependent isozymes, were involved in fMLP/B-induced EPO release but not AA metabolism.
The role of intracellular Ca 2ϩ in stimulated EPO release and LTC 4 secretion was assessed using the cell membrane-permeable Ca 2ϩ chelator BAPTA-AM. BAPTA-AM suppressed both EPO and LTC 4 release in fMLP/B-stimulated eosinophils concentration dependently (Fig. 8) ] i influx was measured in eosinophils by means of the calcium-sensitive fluorescent dye fura 2-AM. As shown in Fig. 9 , addition of fMLP/B caused a transient increase in intracellular calcium and declined to baseline level in Ͻ200 s; ET-18-OCH 3 blocked the increase of [Ca 2ϩ ] i completely.
DISCUSSION
The objective of this investigation was to assess the common and selective mechanisms by which PI-PLC causes both eosinophil degranulation and leukotriene synthesis in isolated human eosinophils. We have suggested previously that both functions were regulated by PLA 2 (28) . These data, however, were obtained before the development of more specific inhibitors of phospholipase isoforms. In these studies, we found that PI-PLC is critical to both fMLP/B-stimulated eosinophil degranulation and leukotriene synthesis and secretion. However, degranulation is likely regulated by PLC-␤ isoform, which is coupled to G protein (Fig. 3) , whereas LTC 4 synthesis is regulated by subsequent activation of cPLA 2 by PI-PLC-induced [Ca 2ϩ ] i . Our findings support the concept that eosinophil degranulation is regulated by PI-PLC activation. We found that EPO release corresponded temporally to PLC activation, as measured by Ins(1,4,5)P 3 production ( Figs. 1 and 4A ). Both EPO release and Ins(1,4,5)P 3 production occurred within 60 s; ET-18-OCH 3 , a selective PI-PLC inhibitor, at a concentration that inhibited Ins(1,4,5)P 3 production, suppressed EPO release (24). Because ET-18-OCH 3 induces rapid apoptosis in tumor cells, whereas normal cells remain unaffected (21) , we demonstrated in this study that cell viability was always Ͼ95%, even at the greatest concentration used, thus excluding nonspecific cytotoxicity as an inhibitory mechanism. Calcium has been shown to play a major role in eosinophil degranulation (15, 16) ; ET-18-OCH 3 at the concentration that suppressed Ca 2ϩ influx, also inhibited EPO release. In contrast to our previous observation (28), we found no evidence in this investigation for regulation of eosinophil degranulation by PLA 2 . In those previous studies, we used mepacrine and BPB to inhibit PLA 2 activity. Although these inhibitors are structurally nonhomologous, they have global inhibitory activity on PLA 2 . We have also noted that mepacrine and BPB also likely have nonspecific inhibitory effects in cell secretion, the mechanism of which has not been defined. To address the role of PLA 2 in regulating eosinophil degranulation in this study, we used selective inhibitors of upstream activation of PLA 2 as well as selective inhibitors of cPLA 2 , which have been developed since the previous investigation. Although our data indicate a selective role for cPLA 2 in cysteinyl LT synthesis in eosinophils, we find no evidence that cPLA 2 regulates degranulation. Previous publications have suggested a potential role of sPLA 2 in regulating eosinophil degranulation (9) , and sPLA 2 is blocked nonselectively by mepacrine and BPB. However, preliminary observations have not indicated that selective blockade of sPLA 2 causes substantial blockade of eosinophil degranulation during activation with fMLP/B (data not shown). Thus, although the use of selective blocking agents clearly demonstrates a role for intracellular calcium and PLC in regulating eosinophil degranulation, we do not find evidence for PLA 2 in this process as suggested in previous studies using less specific enzyme inhibitors.
We also examined the role of PKC in eosinophil degranulation and LTC 4 secretion. Using three different PKC inhibitors (Fig. 8) , we demonstrated suppression of fMLP/B-induced EPO release, suggesting that PKC, possibly the classical Ca 2ϩ -dependent isozymes, plays an important role in eosinophil degranulation. Our findings suggest that fMLP/B-induced eosinophil degranulation is mediated through a PTX-sensitive G protein that activates the PLC pathway (possibly the ␤-isoform). The generation of Ins(1,4,5)P 3 and DAG causes increase in [Ca 2ϩ ] i ( Fig. 9) and activation of PKC. Each step was shown to be required for stimulated eosinophil degranulation in these studies.
In contrast to degranulation of eosinophil protein, leukotriene release from stimulated eosinophils was regulated by both PI-PLC and cPLA 2 activation. cPLA 2 activation requires two signals, serine phosphorylation by mitogen-activated protein kinase and calcium influx (19) . cPLA 2 phosphorylation increases its enzymatic activity, whereas calcium influx causes translocation of cPLA 2 to intracellular membranes (25, 27) . TFMK, which selectively blocks cPLA 2 , also blocked LTC 4 synthesis. Thus leukotriene synthesis caused by PI-PLC depended critically on calcium influx and also subsequently on cPLA 2 activation. Similar results have been reported in human basophils (20) .
We conclude that fMLP/B activates human eosinophils through PTX-sensitive G protein and activates PLC, possibly the ␤2-isoform. This causes generation of Ins(1,4,5)P 3 and DAG, which, in turn, causes an increase in [Ca 2ϩ ] i with subsequent PKC activation. Calcium and PKC activation is required for fMLP/B-induced eosinophil degranulation, whereas LTC 4 secretion is regulated by PLC through calcium-mediated activation of cPLA 2 .
